-- Announcement on Resolutions of the 7th Meeting of the 5th Board of Supervisors
Securities code: 603858 Securities abbreviation: Buchang Pharmaceutical Announcement number: 2025-156
Shandong Buchang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the Seventh Meeting of the Fifth Supervisory Board
The Company's Supervisory Committee and all supervisors guarantee that there are no false records, misleading statements or major omissions in this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The notice of the seventh meeting of the fifth supervisory board of Shandong Buchang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was issued on August 15, 2025. The meeting was held by communication at 14:00 on August 27, 2025. 4 supervisors were supposed to be present, but 4 were actually present. The meeting was chaired by Mr. Wang Minggeng, chairman of the supervisory board. The number of attendees, convening and voting methods of the meeting comply with the relevant provisions of the "Company Law of the People's Republic of China" and other laws and regulations and the "Articles of Association of Shandong Buchang Pharmaceutical Co., Ltd." (hereinafter referred to as the "Articles of Association"), and are legal and valid. After careful deliberation, the supervisors present at the meeting passed the following proposals:
- "Proposal on the Company's 2025 Semi-Annual Report and Summary"
The participating supervisors carefully and rigorously reviewed the 2025 semi-annual report and put forward the following written review opinions. The participating supervisors believed:
(1) The preparation and review procedures of the company’s 2025 semi-annual report comply with various provisions of laws, regulations, the Articles of Association and the company’s internal management system;
(2) The content and format of the company’s 2025 semi-annual report comply with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the information contained can comprehensively and truly reflect the company’s operations, management and financial status and other matters in the 2025 semi-annual report;
(3) No personnel involved in the preparation and review of the 2025 semi-annual report were found to have violated confidentiality regulations.
For details, please refer to the "Shandong Buchang Pharmaceutical Co., Ltd. 2025 Semi-Annual Report" and "Shandong Buchang Pharmaceutical Co., Ltd. 2025 Semi-Annual Report Summary" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
Voting results: 4 votes in favor, 0 votes against, and 0 abstentions.
- "Proposal on the special report on the deposit and actual use of funds raised by the company in the first half of 2025"
In accordance with the relevant provisions of the "Company Law of the People's Republic of China", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations", "Supervisory Rules for Funds Raised by Listed Companies" and the "Articles of Association" and "Shandong Buchang Pharmaceutical Co., Ltd. Raised Funds Management System", the company prepared the "Special Report on the Deposit and Actual Use of Raised Funds of Shandong Buchang Pharmaceutical Co., Ltd. in the 2025 Semi-annual".
For details, please refer to the "Special Report on the Deposit and Actual Use of Raised Funds of Shandong Buchang Pharmaceutical Co., Ltd. for the Half Year of 2025" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) on the same day.
Voting results: 4 votes in favor, 0 votes against, and 0 abstentions.
- "Proposal on the Company's Half-year Profit Distribution in 2025"
In accordance with the "Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends of Listed Companies", the Articles of Association and other relevant provisions, in order to increase investor returns, share operating results, and boost investors' confidence in holding shares, the company has proposed a semi-annual profit distribution plan for 2025 on the premise of complying with the company's profit distribution policy and ensuring the company's normal operations and long-term development.
For details, please refer to the "Announcement of Shandong Buchang Pharmaceutical Co., Ltd.'s 2025 Semi-annual Profit Distribution Plan" disclosed by the company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same day. (Announcement No.: 2025-157)
According to the authorization of the 2024 annual shareholders' meeting, this profit distribution plan does not need to be submitted to the company's shareholders' meeting for review.
Voting results: 4 votes in favor, 0 votes against, and 0 abstentions.
Announcement is hereby made.
Board of Supervisors of Shandong Buchang Pharmaceutical Co., Ltd.
August 28, 2025